Just Published: "Hungary Pharmaceuticals & Healthcare Report Q2 2015"

Hungary's pharmaceutical market will stabilise and grow slightly in 2015. The challenging operating environment, regulatory burden and punitive taxes on the pharmaceutical sector will continue to stunt growth. Pharmaceutical growth in local currency terms will be driven by consumer demand for over-the-counter medicines and greater uptake of generic medicines.

Headline Expenditure Projections

* Pharmaceuticals: HUF579.14bn (USD2.50bn) in 2014 to HUF590.49bn (USD2.31bn) in 2014; +2.0% in local currency terms and -7.9% in US dollar terms.
* Healthcare: HUF2,191bn (USD9.47bn) in 2014 to HUF2,232bn (USD8.72bn) in 2014; +1.9% in local currency terms and -7.9% in US dollar terms.

Risk/Reward Index

Our proprietary Risk/Reward assessment tool has been gradually adjusted to be increasingly transparent and sensitive in relation to potential Rewards. Therefore, as Hungary's market opportunity has worsened, it has slipped down our regional table. Hungary currently ranks ninth out of the 20 regional markets profiled in the Central and Eastern Europe (CEE) region, with a score of 52.4. While its Risks profile is generally predictable, Hungary's Rewards score continues to reflect its challenging pharmaceutical market outlook.

Full Report Details at
- http://www.fastmr.com/prod/953229_hungary_pharmaceuticals_healthcare_report_q2_2015.aspx?afid=301

Key Trends & Developments

* In January 2015, the Hungarian minister for Human Resources stated that the Hungarian government wanted to offer tax advantages to private healthcare providers. The Hungarian state is looking at the private sector to reduce some of the burden on the public healthcare system's finances.
* Only an additional HUF4bn (USD15mn) will be spent by the National Health Insurance Fund (OEP) in 2015 on the reimbursement of medicines than was spent in 2014 (HUF294.1bn). Most of the increase in healthcare expenditure will be directed towards paying overdue debts of hospitals.
* Gedeon Richter warned in December 2014 that the depreciation of the Russian rouble would have a negative impact on its Q414 earnings, with a substantial...

The Hungary Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Hungary Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Hungary pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Hungary, to test other views - a key input for successful budgeting and strategic business planning in the Hungarian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Nigeria Pharmaceuticals & Healthcare Report Q2 2015
- Mexico Pharmaceuticals & Healthcare Report Q2 2015
- Thailand Pharmaceuticals & Healthcare Report Q2 2015
- Croatia Pharmaceuticals & Healthcare Report Q2 2015
- Kenya Pharmaceuticals & Healthcare Report Q2 2015